AI Set To Transform Drug Discovery And Regulation: Department Of Pharmaceuticals
India’s Department of Pharmaceuticals said artificial intelligence is reshaping the pharmaceutical value chain, from early drug discovery to regulatory approval and post-market surveillance.
The Department of Pharmaceuticals under India’s Ministry of Chemicals and Fertilizers highlighted the transformative role of AI in drug discovery, clinical development, regulation and pharmaceutical innovation.
Key facts
- The Department of Pharmaceuticals discussed AI during a webinar held as part of Sādhana Saptah 2026.
- The session was titled “AI and Emerging Technologies in Pharmaceuticals and Regulations”.
- Officials and experts said AI is influencing drug discovery, clinical trials, regulation and post-market safety monitoring.
- Sādhana Saptah 2026 is being organised from April 2 to April 8, 2026 under the broader framework of Mission Karmayogi.
The Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers of India highlighted the transformative role of artificial intelligence in the pharmaceutical sector during a webinar organised as part of Sādhana Saptah 2026. The official government webinar focused on how AI is reshaping the pharmaceutical value chain and how emerging technologies may strengthen India’s pharma ecosystem in the years ahead. :contentReference[oaicite:0]{index=0}
The session, titled “AI and Emerging Technologies in Pharmaceuticals and Regulations,” focused on how AI is reshaping the entire drug development lifecycle, from early-stage research to regulatory approval and post-market surveillance. The Department of Pharmaceuticals said the discussion covered both innovation and regulation, showing how AI tools are increasingly relevant across research, development, evidence generation and oversight. :contentReference[oaicite:1]{index=1}
Addressing the webinar, Prof. Manoj Kumar from the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, outlined how AI is accelerating innovation in drug discovery. He explained that AI tools are enabling faster identification of drug targets, optimization of compounds, and prediction of molecular interactions, significantly reducing both time and cost in early-stage research. :contentReference[oaicite:2]{index=2}
AI is expanding from discovery into clinical development
The discussion also covered the growing use of AI in pre-clinical and clinical stages, including simulation-based modelling, improved clinical trial design, and advanced data analytics for better patient stratification. According to the webinar summary, experts said these applications could improve both the efficiency and the accuracy of clinical outcomes, an important point as pharmaceutical development increasingly depends on faster and more precise decision-making. :contentReference[oaicite:3]{index=3}
Participants were also briefed on advances such as AI-enabled prediction of protein structures, drug-target interactions, toxicity assessment, and drug repurposing. These examples were presented as evidence that AI is no longer limited to narrow research tools, but is becoming part of a broader technology stack supporting more efficient pharmaceutical innovation. :contentReference[oaicite:4]{index=4}
Regulators are also looking at AI for faster approvals and safety monitoring
In the regulatory domain, AI-driven decision support systems are emerging as key tools for evidence generation, faster approvals, and improved drug safety monitoring. The webinar stressed the importance of building institutional capacity within government systems so these technologies can be adopted effectively for evidence-based policymaking, regulatory oversight and administrative decision-making. :contentReference[oaicite:5]{index=5}
The webinar highlighted the transformative potential of AI across the pharmaceutical value chain, spanning drug discovery, development, regulation and post-market monitoring. :contentReference[oaicite:6]{index=6}
The Department said the integration of AI across the pharmaceutical value chain is expected to strengthen India’s position as a global leader in the sector, while also improving access to safe and effective medicines. That framing places AI not only in a scientific context, but also in a national policy and competitiveness context, with implications for industrial growth, public health and regulatory modernization. :contentReference[oaicite:7]{index=7}
Sādhana Saptah 2026 links pharma innovation with public-sector capacity building
The webinar forms part of Sādhana Saptah 2026, a nationwide capacity-building initiative aimed at promoting citizen-centric governance and enhancing administrative efficiency. Government notices say the programme is being organised from April 2 to April 8, 2026, bringing together central ministries, states, and training institutions under the broader framework of Mission Karmayogi to help build a future-ready civil service. :contentReference[oaicite:8]{index=8}
Taken together, the Department of Pharmaceuticals’ message is that AI is set to influence every major stage of the drug lifecycle, from identifying drug candidates and refining compounds to strengthening regulatory review and post-market surveillance. For India’s pharmaceutical sector, the webinar signaled a policy direction in which AI is increasingly viewed as a strategic enabler of faster innovation, stronger regulation and broader access to better medicines. :contentReference[oaicite:9]{index=9}
